公众号 / 文章乳腺MR

乳腺MRI——毫米级竞争中的冠军:MIO乳腺MRI——致密型乳腺女性的首选方法

Breast MRI - The champion in the millimeter league: MIO breast MRI - The method of choice in women with dense breasts.
PubMed 文献 · Eur J Radiol · 2023-08-24

本文为单中心经验总结,介绍以10分钟协议(含T2序列、固定5 ml 1 M对比剂)行高分辨率乳腺MRI的经验。作者认为高分辨率MRI是致密型或极致密型乳腺在所有场景(筛查、评估、随访)中的首选方法,对临床相关DCIS的检出优于其他影像 modality。

要点

  • 高空间分辨率(526×526、672×672或最高1.024×1.024,MIO MRI)对获得最佳结果至关重要。
  • 初次乳腺MRI以形态学特征为病灶评估最重要标准;有既往检查对比时,病灶增大或新发病灶为主要可疑标准。
  • 致密型或极致密型乳腺在所有场景中首选高质量高分辨率MRI;A或B型乳腺在钼靶和超声受限或禁忌等特定情形下MRI可能有帮助。

核心结论

  • 作者根据自身经验认为,高质量高分辨率乳腺MRI是致密型或极致密型乳腺在所有情况(筛查、评估、随访)下的首选方法。
  • 作者称95%或以上的乳腺癌可被MRI检出,剩余5%的MRI隐匿病灶为导管内肿瘤或因相关微钙化而被钼靶显示的微小浸润癌。
  • 作者认为MRI在检出临床相关DCIS(高风险DCIS、中间型)方面优于所有其他影像方法。
  • 作者称以12至24个月间隔连续MRI检查可可靠检出平均大小7-8 mm的浸润性乳腺癌,对应>95%病例区域淋巴结无转移,间期癌发生率<2%。
  • 作者结论认为该策略可能将乳腺癌患者总体终生生存率提高至95%以上,反之死亡率可能降至<5%;并认为应讨论修改乳腺癌肿瘤学治疗指南。

研究设计与样本

  • 本文为单中心经验总结,介绍作者所在机构以MRI作为乳腺一线检查技术的方案与经验。
  • 采用10分钟协议(含T2图像),固定剂量5 ml 1 M对比剂。
  • 使用固定装置避免运动伪影,运动校正算法可在伪影出现时予以消除。
  • 高空间分辨率矩阵为526×526,更佳为672×672,最高为1.024×1.024(MIO MRI)。

关键影像表现/征象

  • 初次乳腺MRI检查中,形态学特征是病灶评估的最重要标准。
  • 有既往检查可供对比时,提示可疑病灶的主要标准为病灶增大或出现新病灶。
  • 乳腺MRI上可检出的病灶包括浸润性癌和DCIS;MRI隐匿病灶为导管内肿瘤或因微钙化被钼靶显示的微小浸润癌。

诊断标准与关键数值

  • 作者经验称95%或以上的乳腺癌可被MRI检出,剩余5%为MRI隐匿病灶(导管内肿瘤或伴微钙化的微小浸润癌)。
  • 以12至24个月间隔连续MRI检查可检出平均大小7-8 mm的浸润性乳腺癌,对应>95%病例区域淋巴结无转移,间期癌发生率<2%。
  • 作者称该策略可能使乳腺癌患者总体终生生存率提高至95%以上,死亡率可能降至<5%。

临床应用与阅片要点

  • 作者所在机构将乳腺MRI作为一线检查技术,采用10分钟协议(含T2图像)和固定剂量5 ml 1 M对比剂。
  • 作者强调高空间分辨率(526×526、更佳672×672、最高1.024×1.024 MIO MRI)对获得最佳结果至关重要。
  • 作者使用固定装置避免运动伪影;运动校正算法可在伪影出现时予以消除。
  • 阅片时初次检查以形态学特征为病灶评估最重要标准;有既往对比时以病灶增大或新发病灶为主要可疑标准。
  • 作者认为致密型或极致密型乳腺在所有场景(筛查、评估、随访)中首选高质量高分辨率MRI;A或B型乳腺在钼靶和超声受限或禁忌等特定情形下MRI可能有帮助。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

We perform MRI of the breast as a first pass technique. We successfully established 10-minute-protocols (including T2 images) with a fixed dosage of 5 ml 1 M CM. A high spatial resolution of 526 × 526, better 672 × 672 or maximum (1.024 × 1.024, MIO MRI) is vital to achieve best results. We use fixation tools to avoid motion artifacts. Motion correction algorithms can, however, often eliminate such artifacts when they are present. In initial breast MRI exams, morphologic features are the most important criteria for lesion evaluation. If previous exams are available for comparison, the main criteria indicating a suspicious lesion are an increase in lesion size or the depiction of new lesions. High quality HR MRI of the breast is the method of choice in women with dense or extremely dense breasts in all cases (screening, assessment, follow up). In density type A or B, MRI can be helpful in defined constellations, e.g. when MX and US are limited or contraindicated. According to our experience, 95% or more of all carcinomas of the breast are detectable on MRI. The remaining 5% of MRI-occult lesions are intraductal tumors or very small invasive carcinomas depicted with mammography due to associated microcalcifications. MRI is, however, superior to all other imaging modalities in the detection of the clinically relevant DCIS (high risk DCIS, intermediate type). Consecutive MRI examinations in intervals of 12 to 24 months allow a reliable detection of invasive breast cancer with an average size of 7-8 mm. This corresponds to a rate of metastasis-free locoregional lymph nodes in >95% of cases. The rate of interval cancers is <2%. In conclusion, this strategy may increase the overall-lifetime survival of breast cancer patients to more than 95%. Inversely, mortality may be reduced to <5%. Taking these improvements in early breast cancer detection and survival that can be achieved through the implementation of QA HR MRI of the breast into account, it should be discussed to modify oncologic guidelines for the treatment of breast cancer. MRI is the best diagnostic tool we have and according to our experience, a first pass, quality-assured high-resolution breast MRI protocol provides best diagnostic results at minimal procedural effort.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Fischer U. Breast MRI - The champion in the millimeter league: MIO breast MRI - The method of choice in women with dense breasts. Eur J Radiol. 2023. PMID: 37659208. doi:10.1016/j.ejrad.2023.111053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。